Forbion Growth Management B.V.
- SEC CIK
- 0001918318
No open-market purchases or sales filed in the past year.
Current role at each company
- NAMS NewAmsterdam Pharma Co N.V.10% Owneras of Jan 2, 2025
- ENGN enGene Therapeutics Inc.10% Owneras of Nov 1, 2024
- Forbion European Acquisition Corp.Director, 10% Owneras of Oct 31, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Forbion Growth Management B.V. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
NAMS NewAmsterdam Pharma Co N.V.
10% Owner9 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 2, 2025 (view filing)4:15 PM ET | Dec 30, 2024 | 3 days | Forbion Capital Fund IV Cooperatief U.A. and 4 others10% Owner | SSale | −29.8K | $25.54 | −$762.2K | −0.3%10.7M after | 10b5-1 |
| Dec 30, 2024 (view filing)4:15 PM ET | Dec 26-27 | 4 days | Forbion Capital Fund IV Cooperatief U.A. and 4 others10% Owner | SSale | −74.9K | $25.98 | −$1.95M | −0.7%10.7M after | 2 lots10b5-1 |
| Dec 26, 2024 (view filing)4:15 PM ET | Dec 20-24 | 6 days | Forbion Capital Fund IV Cooperatief U.A. and 4 others10% Owner | SSale | −91.1K | $25.58 | −$2.33M | −0.8%10.8M after | 4 lots10b5-1 |
| Dec 20, 2024 (view filing)4:25 PM ET | Dec 18-19 | 2 days | Forbion Capital Fund IV Cooperatief U.A. and 4 others10% Owner | SSale | −157.2K | $25.86 | −$4.07M | −1.4%10.9M after | 3 lots10b5-1 |
| Dec 18, 2024 (view filing)4:15 PM ET | Dec 16-17 | 2 days | Forbion Capital Fund IV Cooperatief U.A. and 4 others10% Owner | SSale | −115.5K | $25.95 | −$3.00M | −1.0%11.0M after | 3 lots10b5-1 |
| Dec 16, 2024 (view filing)4:15 PM ET | Dec 12-13 | 4 days | Forbion Capital Fund IV Cooperatief U.A. and 4 others10% Owner | SSale | −191.8K | $25.34 | −$4.86M | −1.7%11.1M after | 3 lots10b5-1 |
| Dec 12, 2024 (view filing)4:15 PM ET | Dec 10-11 | 2 days | Forbion Capital Fund IV Cooperatief U.A. and 4 others10% Owner | SSale | −462.3K | $25.40 | −$11.7M | −3.9%11.3M after | 5 lots10b5-1 |
| Nov 19, 2024 (view filing)4:15 PM ET | Nov 15-18 | 4 days | Forbion Capital Fund IV Cooperatief U.A. and 4 others10% Owner | SSale | −41.8K | $25.07 | −$1.05M | −0.4%11.8M after | 2 lots10b5-1 |
| Nov 15, 2024 (view filing)4:36 PM ET | Nov 13-14 | 2 days | Forbion Capital Fund IV Cooperatief U.A. and 4 others10% Owner | SSale | −10.9K | $25.01 | −$272.5K | −0.1%11.8M after | 2 lots10b5-1 |
ENGN enGene Therapeutics Inc.
10% Owner2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 1, 2024 (view filing)4:15 PM ET | Oct 30 | 2 days | Forbion Growth Opportunities Fund I Cooperatief U.A. and 1 other10% Owner | PPurchase | +561.8K | $8.90 | +$5.00M | +22.7%3.03M after | |
| Oct 18, 2024 (view filing)4:15 PM ET | Dec 27, 2023-Oct 8, 2024 | 296 daysLate | Forbion Growth Opportunities Fund I Cooperatief U.A. and 1 other10% Owner | PPurchase | +470.6K | $6.40 | +$3.01M | +23.5%2.47M after | 13 lots |